Unknown

Dataset Information

0

Value-based pricing: Toward achieving a balance between individual and population gains in health benefits.


ABSTRACT: OBJECTIVES:Value-based pricing of oncology drugs provides a best estimate for the price of a drug, as it relates to the benefits it provides for individual patients. To date, the impact of value-based pricing to reference cost-effectiveness thresholds (?) on individual and population-level health benefits remains uncharacterized. The current study examined the potential benefits of value-based pricing by quantifying the incremental net health benefit (INHB) of publicly funded oncology drugs, if funding occurred at manufacturer-submitted price without value-based pricing. METHODS:Pan-Canadian Oncology Drug Review (pCODR) submissions were reviewed to identify eligible drug indications from which final economic guidance panel reports were reviewed for incremental costs (?C) and quality-adjusted life-years (?QALY) from manufacturer-submitted, pCODR lower-limit (pCODR-LL) and upper-limit (pCODR-UL) re-analyzed estimates. Annual number of cases in Ontario for each drug indication was obtained from population databases. Annual QALY gain per drug indication was determined by (?QALY × cases). Population QALY gain/loss in the absence of value-based pricing to reference ? was estimated by the INHB: (INHB = [?QALY - (?C/?)] × cases). RESULTS:In total, 34 drug indications (4629 cases) were identified. Annual gain in QALYs for the funded drug indications using manufacturer, pCODR-LL, and pCODR-UL estimates was 1851, 1617, and 1301, respectively. At a ? $100 000/QALY, funding in the absence of value-based pricing resulted in loss of 2311, 2519, and 2604 QALYs. This would result in a provincial net annual loss of 460, 902, and 1303 QALYs. CONCLUSIONS:Despite an annual gain in QALY per funded drug indication, a net loss in QALY for the province, in the absence of value-based pricing, was demonstrated. Supportive evidence exists for value-based pricing toward the promotion of health benefits for the greater population.

SUBMITTER: Parmar A 

PROVIDER: S-EPMC6943176 | biostudies-literature | 2020 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

Value-based pricing: Toward achieving a balance between individual and population gains in health benefits.

Parmar Ambica A   Jiao Tina T   Saluja Ronak R   Chan Kelvin K W KKW  

Cancer medicine 20191111 1


<h4>Objectives</h4>Value-based pricing of oncology drugs provides a best estimate for the price of a drug, as it relates to the benefits it provides for individual patients. To date, the impact of value-based pricing to reference cost-effectiveness thresholds (λ) on individual and population-level health benefits remains uncharacterized. The current study examined the potential benefits of value-based pricing by quantifying the incremental net health benefit (INHB) of publicly funded oncology dr  ...[more]

Similar Datasets

| S-EPMC5985668 | biostudies-other
| S-EPMC5134939 | biostudies-literature
| S-EPMC7059551 | biostudies-literature
| S-EPMC4826462 | biostudies-literature
| S-EPMC7214508 | biostudies-literature
| S-EPMC5127493 | biostudies-other
| S-EPMC2736102 | biostudies-literature
| S-EPMC5338272 | biostudies-literature
| S-EPMC10543970 | biostudies-literature
| S-EPMC8369795 | biostudies-literature